The iconic rise of Viagra has consistently remained a example of pharmaceutical success, however its future within the broader sector now presents questions about long-term yields . Alternative versions are eroding patent protection , causing concerns that investing in companies closely tied to Viagra's once-dominant standing could be a speculative